UK value based pricing brings in a "QALY-plus" approach
This article was originally published in Scrip
Executive Summary
Professor Adrian Towse, director of the UK pharma industry association (ABPI)-owned but independent think tank the Office of Health Economics, says the department of health's consultation on value-based pricing for medicines articulates a "QALY-plus" approach as "everyone had been expecting".